Candel Therapeutics, Inc. Common Stock
CADLCandel Therapeutics, Inc. (CADL) is a clinical-stage biopharmaceutical company focused on developing innovative immunotherapies for the treatment of cancer. The company leverages its proprietary oncolytic viral platform to design and develop therapies aimed at stimulating the immune system to recognize and destroy tumors, with a focus on translating these therapies into effective solutions for patients with various types of cancer.
Company News
U.S. stock futures rose on Friday ahead of Q4 GDP data and PCE inflation gauge releases. Markets are pricing in a 94% likelihood of unchanged Fed rates in March. Notable movers include Copart missing earnings expectations, Comfort Systems raising dividends, Grail plunging 47% on weak earnings, Candel Therapeutics declining on stock offering annou...
Candel Therapeutics announced a public offering of 18.3 million shares at $5.45 per share, raising $100 million in gross proceeds. The company plans to use the funds for launch readiness and commercialization of aglatimagene besadenovec for localized prostate cancer, ongoing phase 3 trials in non-small cell lung cancer, and general corporate purp...
Candel Therapeutics (NASDAQ: CADL) announced a proposed $100 million public offering of common stock, with an additional $15 million option for underwriters. The company plans to use proceeds for launch readiness, commercialization activities, and development of aglatimagene for prostate cancer and non-small cell lung cancer, along with general c...
The global oncolytic virotherapy market is projected to grow from USD 49.73 million in 2025 to USD 153.31 million by 2031, with a CAGR of 20.64%. Growth is driven by rising cancer incidence, advances in genetic engineering, and synergistic combination therapies with checkpoint inhibitors. However, host immune system challenges and premature viral...
Candel Therapeutics presented three key research presentations at SITC 2025, highlighting advances in immunotherapy for solid tumors using multi-omics analysis and artificial intelligence, including promising phase 3 clinical trial results for CAN-2409 in prostate cancer and preclinical data from their enLIGHTENâ„¢ Discovery Platform.
